here we go!!!!, page-8

Anteo and BBI Solutions Sign Heads of Terms (HoT)
? HoT signed with BBI Solutions, a global leader in immunoassay development and
manufacturing services
? Anteo and BBI to collaborate on a project investigating the manufacturing and
performance benefits of Mix&Go™ on BBI particles
? Commercial agreement is the anticipated outcome
8th November 2013: Anteo Diagnostics Limited (ASX: ADO) is pleased to announce that the
company has entered into a Heads of Terms (HoT) with BBI Solutions (“BBI”).
Anteo and BBI will together investigate the manufacturing and performance benefits of Anteo’s
Mix&Go technology on BBI particles used in lateral flow applications. It is a paid project, building on
previous work and will progress in agreed phases.
Anteo and BBI expect the HoT will lead to a commercial agreement on successful completion of the
Project. The specific deliverables, milestones and timelines are agreed.
“BBI has been interested in the benefits that may come from the use of Mix&Go in our systems for
some time now,” said BBI Solutions’ Managing Director Fiona Marshall. “Our earlier collaborative
study has supported an assertion that Mix&Go may become part of our our exciting portfolio of
nanoparticles.”
Anteo’s Chief Executive Officer, Dr Geoff Cumming, said, “We are pleased to continue our fruitful
collaboration with BBI and hope to play a part in ensuring their continued prominence in the global
Point of Care diagnostics market. We are confident that the project will be successful and progress
to a binding commercial agreement. This project is another step to achieving our objective of
establishing Mix&Go as the preferred solution for binding proteins in diagnostics.”
About Anteo: Anteo Diagnostics (ASX:ADO) is a surface coating company with a proprietary family
of enabling chemistries called Mix&Go. Mix&Go enables the fast and easy production of superior
surfaces for the biotechnology, diagnostics and pharmaceutical industries.

About BBI: BBI Solutions is part of the Alere group of companies. The BBI Group has been a
trusted partner to some of the world’s foremost diagnostic and healthcare organisations for over 25
years, and has developed a leading reputation in delivering innovative solutions to partners,
particularly at the point-of-care.
Founded upon the success of superior quality and performance of gold reagents, BBI has expanded
to incorporate a full development and manufacturing service successfully delivering over 250
projects since inception. BBI has since grown its services further with the incorporation of a range of
Anteo Diagnostics Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email [email protected] Web www.anteodx.com
diagnostic enzymes and clinical biological reagents. The BBI Group consists of 3 divisions that
deliver excellence in diagnostic assay services and products across a range of sectors, together
with the supply of market-leading consumer healthcare products.
For more information visit: www.the-bbigroup.com
ENDS